Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial
作者： Bing Liu , Jian-wen Huang , Yong Li , Bao-shan Hu , Xu He
DOI: 10.1159/000371522
关键词: Single blind 、 Doxorubicin 、 Oncology 、 Single agent 、 Internal medicine 、 Medicine 、 Hepatocellular carcinoma 、 Gemcitabine 、 Therapeutic regimen
摘要: Objectives: It was the aim of this study to find an optimal therapeutic regimen transarterial chemoembolization (TACE) by comparing efficacy chemoemboli
scilit.net
karger.com参考文章(22)
Bruix J, Malfertheiner P, Omata M, Labrecque D, Fried M, Ferenci P, Piratsivuth T, Modawi Sb, Khan A, Krabshuis J, Sherman M, Carillo Fj, Heathcote J, Thomson A, Hamid S, Le Mair A, Fedail S, Sarin S, Otegbayo Ja, Fleig W, Lau G, Zheng Ss, Kew M, World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. Journal of Gastrointestinal and Liver Diseases. ,vol. 19, pp. 311- 317 ,(2010)
Mathieu Boulin, Séverine Guiu, Bruno Chauffert, Serge Aho, Jean-Pierre Cercueil, François Ghiringhelli, Denis Krause, Philippe Fagnoni, Patrick Hillon, Laurent Bedenne, Boris Guiu, Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma Anti-Cancer Drugs. ,vol. 22, pp. 741- 748 ,(2011) , 10.1097/CAD.0B013E328346A0C5
T.S. Yang, C.H. Wang, R.K. Hsieh, J.S. Chen, M.C. Fung, Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I–II trial Annals of Oncology. ,vol. 13, pp. 1771- 1778 ,(2002) , 10.1093/ANNONC/MDF303
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jiejun Wang, Won Young Tak, Hongming Pan, Karin Burock, Jessie Zou, Dimitris Voliotis, Zhongzhen Guan, None, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology. ,vol. 10, pp. 25- 34 ,(2009) , 10.1016/S1470-2045(08)70285-7
Stephan Zangos, Katrin Eichler, Jörn O. Balzer, Ralf Straub, Renate Hammerstingl, Christopher Herzog, Thomas Lehnert, Mathias Heller, Axel Thalhammer, Martin G. Mack, Thomas J. Vogl, Large-sized hepotocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT) European Radiology. ,vol. 17, pp. 553- 563 ,(2007) , 10.1007/S00330-006-0343-X
Ivo W. Graziadei, Wolfgang Vogel, Treatment of patients infected with chronic hepatitis C genotype 2 and 3: More data, more questions? Hepatology. ,vol. 49, pp. 345- 347 ,(2009) , 10.1002/HEP.22819
Tai-Shen Yang, Yung-Chang Lin, Jen-Shi Chen, Hung-Ming Wang, Chen-Hsu Wang, Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. ,vol. 89, pp. 750- 756 ,(2000) , 10.1002/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R
D. Maxwell Parkin, Freddie Bray, Jacques Ferlay, Paola Pisani, Estimating the world cancer burden: Globocan 2000 International Journal of Cancer. ,vol. 94, pp. 153- 156 ,(2001) , 10.1002/IJC.1440
Joong-Won Park, Young Hwan Koh, Hyun Beom Kim, Hwi Young Kim, Sangbu An, Joon-Il Choi, Sang Myung Woo, Byung-Ho Nam, None, Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma Journal of Hepatology. ,vol. 56, pp. 1336- 1342 ,(2012) , 10.1016/J.JHEP.2012.01.006
Steven R. Alberts, Joel M. Reid, Bruce W. Morlan, Gist H. Farr, John K. Camoriano, David B. Johnson, James R. Enger, Thomas E. Seay, George P. Kim, Gemcitabine and Docetaxel for Hepatocellular Carcinoma American Journal of Clinical Oncology. ,vol. 35, pp. 418- 423 ,(2012) , 10.1097/COC.0B013E318219863B